Go to AAD Home
Donate For Public and Patients Store Search

Go to AAD Home
Welcome!
Advertisement
Advertisement

2022 Innovation Academy: Industry Non-CME Programs


Don't miss the latest from industry at the 2022 Innovation Academy!

The Industry Non-CME (INC) Program at the 2022 AAD Innovation Academy is your chance to learn about the latest from industry. INC Programs take place before and after Innovation Academy sessions and events and are solely developed and delivered by the sponsor. INC programs do not qualify for continuing medical education (CME) credit.

Thursday, July 21

Abbvie logo
Presented by: AbbVie - Platinum Sponsor, view in the Mobile App
Challenging AD Expectations: A Therapy Option That Challenges Treatment Goals for Patients with Refractory, Moderate to Severe Atopic Dermatitis (AD) Who Are Not Adequately Controlled with Other Systemic Drug Products

The goals of this program are to understand the burden of AD, to discuss the efficacy and safety of RINVOQ in patients with moderate to severe AD and to review resources available through RINVOQ Complete

When: Thursday, July 21 | 7:00 p.m. Registration & Meal | 7:30 p.m. Program
Where: Room 118/119/120, Vancouver Convention Centre


Friday, July 22

VisualDX sponsor logo
Presented by: VisualDX
Artificial Intelligence, Clinical Decision Support, and the Future of Dermatology

Understanding how we can lead and advance care for our patients through technology is the focus of this presentation. Participants will gain an understanding of the relationship between clinical decision support, digital reference, and artificial intelligence.

Supported by: Janssen Pharmaceuticals
When: Friday, July 22 | 6:30 a.m. Program
Where: MacKenzie Ballroom | Fairmont Waterfront
View more information.


Bristol Myers Squibb logo
Presented by: Bristol Myers Squibb
PsOphisTYKated Pathways: Understanding the Role of TYK2 in Psoriasis

When: Friday, July 22 | 7:30 p.m. Program
Where: Room 118/119/120, Vancouver Convention Centre


Physicians’ Education Resource, LLC
Presented by: Physicians’ Education Resource, LLC
An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management

Alopecia areata is a common autoimmune disease characterized by hair loss that afflicts approximately 6.8 million individuals in the United States. Currently, there are no FDA-approved treatments for alopecia areata, although several treatments are used off-label to manage it. As the pathophysiology of alopecia areata is increasingly understood, novel therapies are becoming increasingly available.

Supported by: An educational grant from Pfizer Inc.
When: Friday, July 22 | 7:00 p.m. Registration & Meal | 7:30 p.m. Program
Where: MacKenzie Ballroom | Fairmont Waterfront
View more information.


Saturday, July 23

PeerView Live
Presented by: PeerView Institute
Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care?

Join us for this PeerView MasterClass & Practicum in which a panel of PN experts will offer evidence-based, practical guidance on current diagnostic and treatment strategies, and the latest clinical data regarding novel therapies. Their discussion will be enhanced by 3D animation depicting PN pathophysiology plus patient videos that provide compelling perspectives on the burdens of the disease and the experience of treatment.

Supported by: An educational grant from Sanofi and Regeneron Pharmaceuticals
When: Saturday, July 23 | 7:00 a.m. Registration & Breakfast | 7:30 a.m. Program
Where: MacKenzie Ballroom | Fairmont Waterfront
View more information.

Advertisement